

In the Claims:

- 1-7. (Cancelled)
8. (Withdrawn) The method of claim 3, wherein the modulator of Notch signalling is an inhibitor of Notch signalling, and wherein TNF α expression is increased.
9. (Cancelled)
10. (Withdrawn) The method of claim 6, wherein the modulator of Notch signalling is an inhibitor of Notch signalling, and wherein IL-10 expression is reduced.
11. (Cancelled)
12. (Withdrawn) The method of claim 4, wherein the modulator of Notch signalling is an inhibitor of Notch signalling, and wherein IL-5 expression is increased.
13. (Cancelled)
14. (Withdrawn) The method of claim 5, wherein the modulator of Notch signalling is an inhibitor of Notch signalling, and wherein IL-13 expression is increased.
- 15-20. (Cancelled)
21. (Currently amended) A method for reducing a [[TH2]] T help 2 (TH2) immune response in a subject in need thereof comprising administering (i) contacting a cell in which cytokine expression is modified according to claim 1, or of the immune system with a modulator of Notch signalling, to the subject to modify cytokine expression in the cell; and (ii) administering said cell, in which cytokine expression is modified, to the subject to reduce the TH2 immune response in said subject.
22. (Currently amended) A method for reducing a [[TH1]] T help 1 (TH1) immune response in a subject in need thereof comprising administering (i) contacting a cell in which cytokine expression is modified according to claim 1, or of the immune system with a modulator of Notch signalling, to the subject to modify cytokine expression in the cell; and (ii) administering said cell, in which cytokine expression is modified, to the subject to reduce the TH1 immune response in said subject.
23. (Currently amended) A method for treating inflammation, an inflammatory condition or an autoimmune condition, in a subject in need thereof, comprising administering (i) contacting a cell in which cytokine expression is modified according to claim 1, or of the immune system with a modulator of Notch signalling, to the subject to modify cytokine

expression in the cell; and (ii) administering said cell, in which cytokine expression is modified, to the subject to treat the inflammation, inflammatory condition, or autoimmune condition.

24. (Currently amended) The method of claim 23, wherein ~~TNF α expression is reduced in,~~ the modification of cytokine expression in the cell comprises reduction of tumor necrosis factor-alpha (TNF α) expression in the cell or in immune cells of the subject.

25. (Currently amended) ~~[[The]] A method of claim 1 for modifying cytokine expression in cells of the immune system of,~~ wherein the modulator of Notch signalling is administered to the cell *in vivo* in a patient in need thereof, comprising administering a modulator of Notch signalling to said patient to modify cytokine expression of said patient's cells *in vivo*.

26. (Currently amended) ~~[[The]] A method of claim 1, wherein the~~ for modifying cytokine expression in cells of the immune system of a patient in need thereof comprising (i) administering a modulator of Notch signalling is administered to the cell to the cells of said subject *ex-vivo* to modify cytokine expression in said cells; and (ii) administering said cells in which cytokine expression is modified to the subject, after which the cell is administered to a patient in need thereof.

27. (Currently amended) A method for treating a disease associated with excessive TNF α production, excessive ~~[[IL-5]]~~ interleukin-5 (IL-5) production or excessive [[IL-13]] interleukin-13 (IL-13) production, in a subject in need thereof, comprising administering (i) contacting a cell in which cytokine expression is modified according to claim 1, or of the immune system with a modulator of Notch signalling, to the subject to modify cytokine expression in the cell; and (ii) administering said cell, in which cytokine expression is modified, to the subject to treat the disease associated with excessive TNF α production, excessive IL-5 production or excessive IL-13 production.

28. (Currently amended) ~~[[The]] A method of claim 1 for modifying cytokine expression in cells of the immune system comprising contacting a cell of the immune system with a modulator of Notch signalling to modify cytokine expression in the cells, wherein the modulator of Notch signalling comprises a protein or polypeptide comprising a Notch ligand [[DSL]]~~ Delta-Serrate-Lag2 (DSL) domain or a polynucleotide sequence encoding the protein or polypeptide.

29. (Currently amended) The method of claim 28, wherein the protein or polypeptide comprises at least one ~~EGF-like~~ epidermal growth factor-like (EGF-like) domain.

30. (Currently amended) The method of claim 29, wherein the DSL domain ~~and/or EGF or EGF-like~~ domain is from Delta or Jagged.

31. (Withdrawn) The method of claim 1, wherein the modulator of Notch signalling comprises a fusion protein comprising a segment of a Notch ligand extracellular domain and an immunoglobulin FC segment or a polynucleotide encoding said fusion protein.

32. (Withdrawn) The method of claim 1, wherein the modulator of Notch signalling comprises a Notch intracellular domain (Notch IC) or a polynucleotide sequence encoding a Notch IC.

33. (New) A method for reducing a TH2 immune response in a subject in need thereof comprising administering a modulator of Notch signalling to the subject to modify cytokine expression in cells of the immune system of said subject to reduce the TH2 immune response in said subject.

34. (New) A method for reducing a TH1 immune response in a subject in need thereof comprising administering a modulator of Notch signalling to the subject to modify cytokine expression in cells of the immune system of said subject to reduce the TH1 immune response in said subject.

35. (New) A method for treating inflammation, an inflammatory condition, or an autoimmune condition in a subject in need thereof, comprising administering a modulator of Notch signalling to the subject to modify cytokine expression in immune cells of said subject to treat inflammation, inflammatory condition, or autoimmune condition.

36. (New) The method of claim 35, wherein the cytokine expression modification in the immune cells comprises reduction of TNF α expression in the immune cells of said subject.

37. (New) A method for treating a disease associated with excessive TNF α production, excessive IL-5 production or excessive IL-13 production in a subject in need thereof, comprising administering a modulator of Notch signalling to the subject to modify cytokine expression in immune cells of said subject to treat the disease associated with excessive TNF α production, excessive IL-5 production or excessive IL-13 production.

38. (New) The method of claim 29, wherein the DSL domain and EGF-like domain is from Delta or Jagged.